Allarity Therapeutics logo
Allarity Therapeutics
ALLR | NASDAQ
Chart Builder DCF Calculator
$0.88
-$0.07 (-7.74%)
At close: Nov 16, 2026, 4:00 PM ET
$0.94
+$0.06 (+6.41%)
After-hours: Nov 16, 2026, 7:40 PM ET

Allarity Therapeutics Company Profile

Company profile explained

Company Profile

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Key Executives

Name Position
Thomas H. Jensen Founder, Chief Executive Officer & Director
Jeffrey S. Ervin Chief Financial Officer
Jeremy R. Graff President & Chief Development Officer
Jose L. Iglesias Consultant Chief Medical Officer
Steen Meier Knudsen Founder & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 424B5 Filing
Oct 30, 2026 8-K Current Report
Oct 09, 2026 4 Filing
Oct 01, 2026 8-K Current Report
Sep 29, 2026 8-K Current Report
Sep 16, 2026 8-K Current Report
Sep 14, 2026 8-K Current Report
Aug 14, 2026 8-K Current Report
Aug 14, 2026 10-Q Quarterly Report
Jul 01, 2026 8-K Current Report
View All SEC Filings ➞
Allarity Therapeutics
Allarity Therapeutics logo
Country United States
IPO Date Dec 21, 2021
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Thomas H. Jensen

Contact Details

123 E. Tarpon Ave. Tarpon Springs, Florida 34689 United States

Stock Details

Ticker Symbol ALLR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001860657
CUSIP Number 016744500
ISIN Number US0167445008
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.